Turalio Dosing Regimen Updated for Tenosynovial Giant Cell Tumor
A new dosing regimen for Turalio (pexidartinib) is available for the treatment of adults with symptomatic tenosynovial giant cell tumor.
Diagnosis & Disease Information
Tecentriq Approved for Unresectable or Metastatic Alveolar Soft Part Sarcoma
The approval was based on data from a phase 2 study that included 49 patients with unresectable or metastatic ASPS.
American Cancer Society 2021 Statistics Report Shows Continuous Decline in Cancer Mortality Rate, Illuminates Disease-Specific Trends
The American Cancer Society’s annual report approximates the new cancer diagnoses and deaths expected in 2021 and identifies impactful patterns in oncology care.
Researchers Turn to Crowdsourcing to Learn More About COVID-19 and Cancer
Pooling data from physicians and patients appears to be an efficient way to answer urgent questions.
Anorexia, Hypertension, Pneumothorax, and Hypothyroidism: Potential Signs of Improved Clinical Outcome Following Apatinib in Advanced Osteosarcoma
[Cancer Management and Research] A single-institution study that evaluated the efficacy and safety of apatinib, a specific TKI, in patients aged 16 years and older with advanced osteosarcoma progressing on chemotherapy showed that some AEs may be markers for improved PFS and clinical benefit rate.
The Disappointing Reality of Crowdfunding Cancer Care
If crowdfunding doesn’t work, here’s how oncologists can help patients with financial toxicity.
Some Targeted Therapies May Miss the Mark
Ten different drugs continued to kill cancer cells even when their target proteins were removed.
Enhanced Reimbursement Incentives for Generic Cancer Drugs Found Not to Affect Prescribing Patterns
Critics of the study say they are not surprised by the study’s conclusions, as oncologists make treatment decisions based on best treatment course, not money.
Bone Cancer (Fact Sheet)
This fact sheet reviews bone cancer, including its possible causes, frequency, symptoms, diagnosis, and treatment.
Cisplatin-Induced Adverse Events in Osteosarcoma Not Improved With Pantoprazole
This phase 2 study sought to determine whether concurrent pantoprazole would improve cisplatin-induced ototoxicity and nephrotoxicity in younger patients with osteosarcoma.
- Loading...
Loading...
Next post in Side-Effect Management
Loading... 
Loading...